Results 1 to 10 of about 218,133 (348)

Drugs for treating myocardial fibrosis

Frontiers in Pharmacology, 2023
Myocardial fibrosis, which is a common pathological manifestation of many cardiovascular diseases, is characterized by excessive proliferation, collagen deposition and abnormal distribution of extracellular matrix fibroblasts.
Zhanhong Ren, Zixuan Zhang, Zixuan Zhang, Li Ling, Xiufen Liu, Xin Wang   +5 more
doaj   +3 more sources

Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance [PDF]

Journal of Cardiovascular Magnetic Resonance, 2011
Background Heart failure remains a major cause of mortality in thalassaemia major. The possible role of cardiac fibrosis in thalassemia major in the genesis of heart failure is not clear.
Tanner Mark A, Carpenter John, Kirk Paul, Pennell Dudley J   +3 more
doaj   +3 more sources

RNA 5-Methylcytosine Modification in Myocardial Fibrosis [PDF]

Reviews in Cardiovascular Medicine
Myocardial fibrosis represents a common pathological hallmark of various cardiovascular diseases progressing to heart failure, with the immunoinflammatory response playing a pivotal role in the pathogenesis of myocardial fibrosis.
Bohan Li, Yan Hao, Wendan Tian, Wei Liu
doaj   +2 more sources

Myocardial fibrosis in stroke survivors [PDF]

International Journal of Cardiology, 2015
Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death ...
Allgar, V., MacWalter, R., McSwiggan, S., Struthers, A. D., Sze, S., Wong, K., Wong, S.   +6 more
core   +5 more sources

Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis [PDF]

Acta Pharmaceutica Sinica B
Myocardial fibrosis is a serious cause of heart failure and even sudden cardiac death. However, the mechanisms underlying myocardial ischemia-induced cardiac fibrosis remain unclear.
Xuewen Yang, Yanwei Zhang, Xiaoping Leng, Yanying Wang, Manyu Gong, Dongping Liu, Haodong Li, Zhiyuan Du, Zhuo Wang, Lina Xuan, Ting Zhang, Han Sun, Xiyang Zhang, Jie Liu, Tong Liu, Tiantian Gong, Zhengyang Li, Shengqi Liang, Lihua Sun, Lei Jiao, Baofeng Yang, Ying Zhang   +21 more
doaj   +2 more sources

Myocardial fibrosis in primary aldosteronism. [PDF]

Front Endocrinol (Lausanne)
ObjectiveWe investigated myocardial fibrosis in relation to clinical and biochemical characteristics and the metabolomics in patients with primary aldosteronism.MethodsOur study included 54 patients with primary aldosteronism. We performed cardiac magnetic resonance to evaluate focal replacement myocardial fibrosis defined as late gadolinium ...
Chen YL, Chen CH, Ye XF, Xu JZ, Zhu LM, Xu TY, Li Y, Wang JG.   +7 more
europepmc   +4 more sources

LncRNA FTX promotes myocardial fibrosis by sponging miR-335-3p to regulate TFEC/ILK signaling [PDF]

Scientific Reports
Myocardial fibrosis is a pivotal contributor to heart failure progression. This study aimed to investigate the molecular mechanisms underlying the role of transcription factor EC (TFEC) in myocardial fibrosis.
Feng Yao, Zhongkai He, Chongzhou Zheng, Kunpeng Zhu, Ziliang Zhu, Jianzeng Dong   +5 more
doaj   +2 more sources

Effects of nicorandil on inflammatory response, oxidative stress and myocardial fibrosis after myocardial infarction [PDF]

BMC Cardiovascular Disorders
Introduction Numerous studies have established the potential of nicorandil in alleviating myocardial fibrosis subsequent to myocardial infarction. Nevertheless, the precise mechanism underlying this effect remains incompletely elucidated. This study aims
Junrong Peng, Longjiang Hu, Peng Xiao, Tengxiao Xiang, Mei Huang, Renrong Li, Jiesen Lei, Zhihong Yang, Xiaojia Dai   +8 more
doaj   +2 more sources

Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction

Journal of Cardiovascular Development and Disease, 2023
(1) Background: Chronic inflammation and fibrosis are key players in cardiac remodeling associated with left ventricular hypertrophy (LVH) and heart failure with a preserved ejection fraction (HFpEF). Monocytes and T-helpers (Th) are involved in both pro-
Artem Ovchinnikov, Anastasiya Filatova, Alexandra Potekhina, Tatiana Arefieva, Anna Gvozdeva, Fail Ageev, Evgeny Belyavskiy   +6 more
doaj   +1 more source

Immunomodulation of Myocardial Fibrosis

JACC: Basic to Translational Science, 2023
Immunotherapy is a potential cornerstone in the treatment of myocardial fibrosis. During a myocardial insult or heart failure, danger signals stimulate innate immune cells to produce chemokines and profibrotic cytokines, which initiate self-escalating inflammatory processes by attracting and stimulating adaptive immune cells. Stimulation of fibroblasts
Sikking, Maurits A., Stroeks, Sophie L.VM., Marelli-Berg, Federica, Heymans, Stephane R.B., Ludewig, Burkhard, Verdonschot, Job A.J.   +5 more
openaire   +4 more sources